Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).	Disease Attributes, Esthesioneuroblastoma, Olfactory, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, astrocytoma (excluding glioblastoma), central nervous system cancer, connective tissue neoplasm, cranial nerve neuropathy, diffuse intrinsic pontine glioma, endocrine system disorder, ependymoma, epithelial neoplasm, glioblastoma, glioma, malignant endocrine neoplasm, medulloblastoma, meningioma, neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, olfactory nerve disorder, osteosarcoma, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor, sarcoma, synovial sarcoma, tumor of meninges, vascular cancer	Recruiting	Phase 1 / Phase 2	2026-06-04		NCT06607692

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fundación de investigación HM	5

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
HM Monteprincipe	Boadilla del Monte	Spain	1